MX2018003234A - Metodos y materiales para la terapia genica galgt2. - Google Patents
Metodos y materiales para la terapia genica galgt2.Info
- Publication number
- MX2018003234A MX2018003234A MX2018003234A MX2018003234A MX2018003234A MX 2018003234 A MX2018003234 A MX 2018003234A MX 2018003234 A MX2018003234 A MX 2018003234A MX 2018003234 A MX2018003234 A MX 2018003234A MX 2018003234 A MX2018003234 A MX 2018003234A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- gene therapy
- galgt2
- raav
- materials
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
- C12Y204/01165—N-Acetylneuraminylgalactosylglucosylceramide beta-1,4-N-acetylgalactosaminyltransferase (2.4.1.165)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
- C12N15/8645—Adeno-associated virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente divulgación se refiere a la administración de virus adeno-asociado recombinante (rAAV) de un polinucleótido GALGT2. La divulgación proporciona rAAV y métodos de uso de rAAV para la terapia génica GALGT2 de trastornos neuromusculares. Los trastornos neuromusculares de ejemplo incluyen, pero no se limitan a, distrofias musculares tales como Distrofia muscular de Duchenne, Distrofia muscular congénita 1A y Distrofia muscular de la columna y extremidades 2D.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562220107P | 2015-09-17 | 2015-09-17 | |
US201562221068P | 2015-09-20 | 2015-09-20 | |
US201662301260P | 2016-02-29 | 2016-02-29 | |
PCT/US2016/052051 WO2017049031A1 (en) | 2015-09-17 | 2016-09-16 | Methods and materials for galgt2 gene therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018003234A true MX2018003234A (es) | 2018-09-07 |
Family
ID=58289891
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018003234A MX2018003234A (es) | 2015-09-17 | 2016-09-16 | Metodos y materiales para la terapia genica galgt2. |
Country Status (15)
Country | Link |
---|---|
US (2) | US10980897B2 (es) |
EP (1) | EP3350331A4 (es) |
JP (2) | JP7338970B2 (es) |
KR (1) | KR20180084747A (es) |
CN (1) | CN108136049A (es) |
AU (2) | AU2016323575B2 (es) |
BR (1) | BR112018005177A2 (es) |
CA (1) | CA2998636A1 (es) |
CO (1) | CO2018003960A2 (es) |
EA (1) | EA201890543A1 (es) |
HK (1) | HK1257519A1 (es) |
IL (1) | IL258005A (es) |
MX (1) | MX2018003234A (es) |
SA (1) | SA518391113B1 (es) |
WO (1) | WO2017049031A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA45477A (fr) | 2016-04-15 | 2019-02-20 | Res Inst Nationwide Childrens Hospital | Administration à vecteurs de virus adéno-associé de microarn-29 et micro-dystrophine pour traiter la dystrophie musculaire |
JP7213238B2 (ja) | 2017-10-18 | 2023-01-26 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | 筋ジストロフィーを治療するための筋特異的マイクロジストロフィンのアデノ随伴ウイルスベクター送達 |
WO2019079755A1 (en) | 2017-10-20 | 2019-04-25 | Research Institute At Nationwide Children's Hospital | METHODS AND MATERIALS FOR NT-3 GENE THERAPY |
EP3807309A1 (en) * | 2018-06-18 | 2021-04-21 | Research Institute at Nationwide Children's Hospital | Recombinant adeno-associated virus products and methods for treating dystroglycanopathies and laminin-deficient muscular dystrophies |
EP4051324A4 (en) * | 2019-10-28 | 2023-11-29 | University Of Florida Research Foundation, Incorporated | GENE THERAPY VECTORS |
EP4230196A1 (en) | 2022-02-21 | 2023-08-23 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of dystrophinopathies |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
US5837484A (en) | 1993-11-09 | 1998-11-17 | Medical College Of Ohio | Stable cell lines capable of expressing the adeno-associated virus replication gene |
CA2176117C (en) | 1993-11-09 | 2006-01-03 | Terence R. Flotte | Generation of high titers of recombinant aav vectors |
US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
US5856152A (en) | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
WO1996017947A1 (en) | 1994-12-06 | 1996-06-13 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant aav vectors |
FR2737730B1 (fr) | 1995-08-10 | 1997-09-05 | Pasteur Merieux Serums Vacc | Procede de purification de virus par chromatographie |
US6143548A (en) | 1995-08-30 | 2000-11-07 | Genzyme Corporation | Chromatographic purification of adeno-associated virus (AAV) |
EP0850313B8 (en) | 1995-09-08 | 2009-07-29 | Genzyme Corporation | Improved aav vectors for gene therapy |
US5910434A (en) | 1995-12-15 | 1999-06-08 | Systemix, Inc. | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant |
AU723497C (en) | 1996-09-06 | 2001-10-11 | Trustees Of The University Of Pennsylvania, The | Method for recombinant adeno-associated virus-directed gene therapy |
US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
DK1009808T3 (da) | 1997-09-05 | 2013-01-21 | Genzyme Corp | Fremgangsmåder til generering af hjælper-frie præparater af rekombinante aav-vektorer med høj titer |
US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
WO2001083692A2 (en) | 2000-04-28 | 2001-11-08 | The Trustees Of The University Of Pennsylvania | Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids |
US20060194265A1 (en) * | 2001-10-23 | 2006-08-31 | Morris David W | Novel therapeutic targets in cancer |
WO2008048986A2 (en) * | 2006-10-17 | 2008-04-24 | Children's Hospital Medical Center | Gene array technique for predicting response in inflammatory bowel diseases |
-
2016
- 2016-09-16 MX MX2018003234A patent/MX2018003234A/es unknown
- 2016-09-16 JP JP2018513504A patent/JP7338970B2/ja active Active
- 2016-09-16 EA EA201890543A patent/EA201890543A1/ru unknown
- 2016-09-16 CA CA2998636A patent/CA2998636A1/en active Pending
- 2016-09-16 US US15/759,474 patent/US10980897B2/en active Active
- 2016-09-16 KR KR1020187010628A patent/KR20180084747A/ko not_active Application Discontinuation
- 2016-09-16 AU AU2016323575A patent/AU2016323575B2/en active Active
- 2016-09-16 CN CN201680054261.9A patent/CN108136049A/zh active Pending
- 2016-09-16 WO PCT/US2016/052051 patent/WO2017049031A1/en active Application Filing
- 2016-09-16 BR BR112018005177A patent/BR112018005177A2/pt active Search and Examination
- 2016-09-16 EP EP16847351.0A patent/EP3350331A4/en active Pending
-
2018
- 2018-03-11 IL IL258005A patent/IL258005A/en unknown
- 2018-03-13 SA SA518391113A patent/SA518391113B1/ar unknown
- 2018-04-13 CO CONC2018/0003960A patent/CO2018003960A2/es unknown
- 2018-12-21 HK HK18116463.4A patent/HK1257519A1/zh unknown
-
2021
- 2021-03-16 US US17/203,232 patent/US20210220484A1/en active Pending
- 2021-11-05 JP JP2021180893A patent/JP2022010079A/ja active Pending
-
2023
- 2023-01-31 AU AU2023200499A patent/AU2023200499A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3350331A1 (en) | 2018-07-25 |
CN108136049A (zh) | 2018-06-08 |
US20210220484A1 (en) | 2021-07-22 |
US20180250423A1 (en) | 2018-09-06 |
AU2023200499A1 (en) | 2023-06-15 |
EP3350331A4 (en) | 2019-01-23 |
JP2018527365A (ja) | 2018-09-20 |
SA518391113B1 (ar) | 2022-10-25 |
JP7338970B2 (ja) | 2023-09-05 |
CO2018003960A2 (es) | 2018-10-10 |
WO2017049031A1 (en) | 2017-03-23 |
BR112018005177A2 (pt) | 2018-10-09 |
CA2998636A1 (en) | 2017-03-23 |
KR20180084747A (ko) | 2018-07-25 |
AU2016323575B2 (en) | 2022-10-27 |
IL258005A (en) | 2018-05-31 |
AU2016323575A1 (en) | 2018-04-05 |
EA201890543A1 (ru) | 2018-08-31 |
US10980897B2 (en) | 2021-04-20 |
JP2022010079A (ja) | 2022-01-14 |
HK1257519A1 (zh) | 2019-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018003234A (es) | Metodos y materiales para la terapia genica galgt2. | |
MX2021002845A (es) | Suministro de virus adeno-asociado recombinante de construcciones de polinucleotido u7snrna dirigido a exon 2. | |
PH12017502255A1 (en) | Nrf2 regulators | |
WO2017062835A3 (en) | Compositions and methods for treating duchenne muscular dystrophy and related disorders | |
EP3442601A4 (en) | ADENO-ASSOCIATED VIRUS DELIVERY OF MICRO-RNA-29 TO TREAT MUSCLE DYSTROPHY | |
MX2018002315A (es) | Anticuerpos anti muerte programada 1 (pd 1) y metodos de uso de los mismos. | |
EP3596222A4 (en) | ADENO-ASSOCIATED VIRUS VECTOR ADMINISTRATION OF MUSCLE SPECIFIC MICRODYSTROPHIN FOR THE TREATMENT OF MUSCLE DYSTROPHY | |
MX2018002990A (es) | Uso de la akkermansia pasteurizada para tratar trastornos metabolicos. | |
MX2017005252A (es) | Metodos para la preparacion de ribosidos. | |
EP3995581A3 (en) | Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders | |
EP4219728A3 (en) | Enhanced delivery of viral particles to the striatum and cortex | |
MY184586A (en) | Adenoassociated virus vectors for the treatment of mucopolysaccharidoses | |
PH12016502248A1 (en) | Adenoassociated virus vectors for the treatment of lysosomal storage disorders | |
MX2016002571A (es) | Regulador de ph de transduccion. | |
IN2014DN08812A (es) | ||
MX2020010694A (es) | Particulas de raav que codifican mir-708 y usos del mismo. | |
MY190145A (en) | Isocyanate-free reactive polyurethane compositions | |
MX2020010991A (es) | Composicion para la estimulacion ovarica controlada. | |
MX2018000352A (es) | 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b. | |
MX2017010883A (es) | Composicion para el tratamiento de la infertilidad. | |
EP3375450A4 (en) | COMPOSITION FOR THE TREATMENT OF APOPLEXIA OVER NASAL ADMINISTRATION | |
EP3307891B8 (en) | Combined therapy for duchenne muscular dystrophy | |
EP3697915A4 (en) | ADENO-ASSOCIATED VIRUS VECTOR ADMINISTRATION OF MUSCLE SPECIFIC MICRODYSTROPHIN FOR THE TREATMENT OF MUSCLE DYSTROPHY | |
TW201713686A (en) | Methods for preparing modified von Willebrand factor | |
TN2016000177A1 (en) | P-substituted asymmetric ureas and medical uses thereof |